Mod GRF 1-29: The Short-Acting CJC-1295 Explained

CJC-1295 and GHRH Analogs

30 min

Mod GRF 1-29 has a half-life of approximately 30 minutes, compared to 8 days for CJC-1295 with DAC and under 10 minutes for native GHRH.

Teichman et al., JCEM, 2006

Teichman et al., JCEM, 2006

View as image

Mod GRF 1-29 is a synthetic analog of growth hormone-releasing hormone (GHRH) truncated to its first 29 amino acids and modified at four positions to resist enzymatic degradation. It is commonly called "CJC-1295 without DAC" in peptide communities, though this name is technically imprecise. The compound stimulates pulsatile growth hormone release from the anterior pituitary by binding the GHRH receptor, producing GH pulses that mimic the body's natural secretion pattern more closely than long-acting alternatives. For the broader context of how CJC-1295 stimulates growth hormone and the differences between CJC-1295 with and without DAC, see the dedicated articles. The pillar article on CJC-1295 and IGF-1 elevation covers the full evidence base.

What Mod GRF 1-29 actually is

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid peptide produced in the hypothalamus. It stimulates GH synthesis and secretion by binding to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. Native GHRH has a half-life of less than 10 minutes because it is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) at the second amino acid position.

The first 29 amino acids of GHRH contain the full biological activity of the peptide. Sermorelin (GRF 1-29) was the first truncated GHRH analog developed for clinical use. It retained full GHRH receptor binding but still had a very short half-life (approximately 11-12 minutes) because it contained the same DPP-IV cleavage site as native GHRH. For background on sermorelin as the original GH releasing peptide, see the dedicated article.

Mod GRF 1-29 (also called tetrasubstituted GRF 1-29) adds four amino acid substitutions to the sermorelin sequence:

• Position 2: Alanine replaced with D-alanine (blocks DPP-IV cleavage, the primary degradation pathway)
• Position 8: Asparagine replaced with glutamine (prevents asparagine rearrangement and deamidation)
• Position 15: Glycine replaced with alanine (enhances bioactivity and receptor binding)
• Position 27: Methionine replaced with leucine (prevents methionine oxidation during storage)

These modifications increase the peptide's half-life to approximately 30 minutes while preserving its selectivity for the GHRH receptor and its ability to stimulate pulsatile GH release.

Mod GRF 1-29 vs. CJC-1295 with DAC

The naming confusion between these compounds causes persistent misunderstanding. They are related but pharmacologically distinct.

CJC-1295 with DAC is the compound studied in published clinical trials by Teichman et al. (2006).^[1] DAC (Drug Affinity Complex) is a maleimidopropionic acid linker that allows the peptide to bind covalently to circulating albumin after injection. This albumin binding extends the half-life from minutes to approximately 8 days. The result is continuous, non-pulsatile GHRH receptor stimulation over nearly a week from a single injection.

Mod GRF 1-29 has no DAC component. It does not bind albumin. Its 30-minute half-life means it produces a discrete GH pulse that rises, peaks, and falls within 2-3 hours of injection. Multiple daily injections are needed to produce sustained effects.

The practical difference: CJC-1295 with DAC produces chronically elevated GH and IGF-1 levels (similar to a sustained infusion). Mod GRF 1-29 produces intermittent GH spikes (similar to natural pulsatile secretion). Whether pulsatile or continuous GH stimulation produces better outcomes remains an open question with limited direct comparison data.

Ionescu et al. (2006) published a study demonstrating that pulsatile GH secretion persists even during continuous GHRH receptor stimulation by CJC-1295 with DAC.^[2] This finding suggests the pituitary has intrinsic pulsatile mechanisms that are maintained regardless of whether the GHRH signal is intermittent or continuous. But whether the amplitude, timing, and downstream effects of those pulses are identical under both conditions is unknown.

The clinical data: what exists and what doesn't

CJC-1295 with DAC (the compound that was actually studied)

Teichman's 2006 study remains the primary human pharmacological dataset for any CJC-1295 variant. Two randomized, placebo-controlled, double-blind ascending dose trials examined CJC-1295 with DAC in healthy adults over 28 and 49 days.^[1] Key findings:

• A single subcutaneous injection produced dose-dependent GH increases lasting 6 or more days
• IGF-1 levels increased 1.5 to 3-fold and remained elevated for 9-11 days after injection
• GH and IGF-1 responses were maintained with repeated weekly dosing (no tachyphylaxis)
• No serious adverse events occurred; injection site reactions were the most common complaint
• The DAC modification successfully extended the half-life to approximately 8 days

Alba et al. (2006) confirmed that once-daily CJC-1295 administration in GHRH knockout mice normalized linear growth, demonstrating that the compound could functionally replace endogenous GHRH signaling.^[3]

Sackmann-Sala et al. (2009) showed that CJC-1295 with DAC activated the GH/IGF-1 axis and resulted in changes in serum protein profiles consistent with GH effects, including alterations in proteolytic pathways and inflammatory markers.^[4]

Mod GRF 1-29 (limited data)

Here is the critical gap: no published clinical trial has specifically studied Mod GRF 1-29 as a standalone compound in humans. The human data for CJC-1295 comes from the DAC-conjugated version. The pharmacological properties of Mod GRF 1-29 are inferred from:

1. The known pharmacology of GHRH and sermorelin (the unmodified GRF 1-29)
2. The structural modifications that are understood to extend half-life
3. The CJC-1295 with DAC data (which uses the same core peptide sequence)

This means claims about Mod GRF 1-29's clinical effects are extrapolations from related compounds, not direct evidence. The peptide likely stimulates GH release through the GHRH receptor (that mechanism is well-established for all GRF analogs), but the specific magnitude, duration, and safety profile of Mod GRF 1-29 at common doses have not been characterized in controlled human studies.

Why pulsatile GH matters

The appeal of Mod GRF 1-29 over CJC-1295 with DAC centers on pulsatile versus continuous GH stimulation. This distinction has biological significance.

Endogenous GH is secreted in pulses, with the largest pulse occurring during deep sleep and additional pulses triggered by exercise, fasting, and stress. This pulsatile pattern is not random; it appears to be important for how target tissues respond to GH. Stanley et al. (2011) studied a GHRH analog and found that it increased endogenous GH pulsatility while improving insulin sensitivity in older adults, suggesting that pulse-like GH stimulation may have different metabolic consequences than continuous exposure.^[5]

Continuous GH exposure, as seen in acromegaly, leads to insulin resistance, fluid retention, carpal tunnel syndrome, and increased cardiovascular risk. Pulsatile GH exposure may produce anabolic effects (muscle growth, fat metabolism) with less metabolic disruption. This is the theoretical advantage of Mod GRF 1-29's short half-life: each injection creates a brief GH pulse rather than sustained elevation.

Whether this theoretical advantage translates to clinical benefit has not been tested. No head-to-head trial has compared pulsatile (Mod GRF) versus continuous (CJC-1295 with DAC) GHRH receptor stimulation for any outcome.

Combination with GHRPs: the rationale

Mod GRF 1-29 is commonly combined with growth hormone releasing peptides (GHRPs) like ipamorelin, GHRP-2, or GHRP-6. The rationale is mechanistic: GHRH analogs and GHRPs stimulate GH release through different receptors (GHRHR and GHS-R1a/ghrelin receptor, respectively), and combining both pathways produces a synergistic GH pulse greater than either alone.

This synergy has been demonstrated for GHRH + GHRP combinations in general. Bowers and others showed that co-administration of GHRH and GHRPs produces GH responses 2-3 times greater than either peptide alone. For a detailed comparison of how GHRPs activate the ghrelin receptor, see the dedicated article. The article on ipamorelin's selectivity profile explains why it is the most common GHRP paired with Mod GRF.

However, no published study has specifically tested the combination of Mod GRF 1-29 + ipamorelin in humans. The synergy data comes from studies using native GHRH or sermorelin with various GHRPs. The assumption that Mod GRF 1-29 produces the same synergy is pharmacologically reasonable but not directly proven.

Detection and anti-doping

GH peptides including GHRH analogs are banned by WADA under the S2 category (peptide hormones, growth factors, and related substances). Henninge et al. (2010) developed methods to identify CJC-1295 in pharmaceutical preparations and biological samples.^[6] Timms et al. (2019) created an immuno-polymerase chain reaction screen for detecting CJC-1295 and other GHRH analogs in doping samples.^[7]

Mod GRF 1-29's short half-life makes it harder to detect in routine anti-doping testing compared to CJC-1295 with DAC, which persists in circulation for days. This detection asymmetry is one reason Mod GRF 1-29 has become more popular in competitive sports contexts, though its use remains prohibited. For the broader context of why GH secretagogues are banned in sports, see the anti-doping article.

GHRH analogs beyond bodybuilding

The pharmaceutical development of GHRH analogs has continued in therapeutic contexts distinct from body composition optimization.

Recinella et al. (2020) demonstrated that a GHRH analog produced anti-inflammatory, antioxidant, and behavioral effects in animal models, suggesting applications beyond GH stimulation.^[8]

Schally et al.'s 2025 review traced the development of GHRH analogs from GH-releasing compounds to cancer therapeutics, documenting how GHRH antagonists (not agonists) have shown anti-tumor activity across multiple cancer types.^[9] This represents a different branch of GHRH pharmacology from Mod GRF 1-29, but it illustrates the breadth of biological activity mediated through GHRH receptors.

Tesamorelin (Egrifta), the only FDA-approved GHRH analog, uses a trans-3-hexenoic acid modification to extend half-life. Badran et al.'s 2026 study confirmed its effects on body composition and hepatic fat in HIV-associated lipodystrophy.^[10] Tesamorelin's approval demonstrates that GHRH receptor agonism is a viable therapeutic strategy; Mod GRF 1-29 simply never went through the regulatory process needed to reach a similar status. For a comprehensive overview of CJC-1295 as a GHRH analog, see the introductory article.

The evidence gap in plain terms

Mod GRF 1-29 sits in an unusual position: its mechanism of action is well-understood (GHRH receptor agonism), its pharmacological properties are predictable from related compounds, but its specific clinical effects have never been formally studied in humans. People who use it are making reasonable pharmacological extrapolations from sermorelin, CJC-1295 with DAC, and tesamorelin data. But "reasonable extrapolation" is not the same as "clinical evidence."

The compound's 30-minute half-life, pulsatile GH release pattern, and GHRH receptor selectivity make it mechanistically appealing. Whether these theoretical advantages produce better outcomes than alternatives remains untested in any controlled trial.

Van Hout and Hearne (2016) documented online communities of female CJC-1295 users through netnographic research, finding that users shared detailed self-experimentation protocols, dosing schedules, and side effect reports.^[11] This underground knowledge base fills the gap left by absent clinical trials, but it lacks the controls, standardization, and follow-up that formal research provides. The disconnect between widespread community use and minimal published clinical data defines Mod GRF 1-29's current position in the peptide landscape.

The Bottom Line

Mod GRF 1-29 is a four-substitution modified GHRH fragment that extends half-life from under 10 minutes to approximately 30 minutes while preserving pulsatile GH secretion. It is pharmacologically distinct from CJC-1295 with DAC, which uses albumin binding to sustain GH elevation for approximately 8 days. All published human clinical data on CJC-1295 comes from the DAC version; Mod GRF 1-29 itself has no published human trials. Its use is based on reasonable pharmacological inference from related compounds, not direct clinical evidence.

Frequently Asked Questions

What is Mod GRF 1-29?

Mod GRF 1-29 (also called tetrasubstituted GRF 1-29 or CJC-1295 without DAC) is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone with four amino acid substitutions that resist enzymatic degradation. It has a half-life of approximately 30 minutes and stimulates pulsatile growth hormone release through the GHRH receptor on pituitary somatotroph cells.

Is Mod GRF 1-29 the same as CJC-1295?

No. CJC-1295 refers to the DAC-conjugated version that binds albumin and has an 8-day half-life. Mod GRF 1-29 uses the same core peptide sequence but without the Drug Affinity Complex (DAC). The 30-minute half-life of Mod GRF 1-29 produces brief GH pulses, while CJC-1295 with DAC produces sustained GH elevation. They share GHRH receptor agonism but differ in pharmacokinetics.

What is the difference between Mod GRF 1-29 and sermorelin?

Both are 29-amino-acid GHRH fragments. Sermorelin (GRF 1-29) has the native GHRH sequence and a half-life of 11-12 minutes. Mod GRF 1-29 has four amino acid substitutions that block enzymatic degradation and extend its half-life to approximately 30 minutes. The modifications prevent DPP-IV cleavage, asparagine deamidation, and methionine oxidation.

Has Mod GRF 1-29 been studied in clinical trials?

No published clinical trial has studied Mod GRF 1-29 specifically in humans. The clinical data for CJC-1295 comes from the DAC-conjugated version studied by Teichman et al. (2006). Mod GRF 1-29's properties are inferred from the pharmacology of sermorelin, native GHRH, and CJC-1295 with DAC. Users are relying on pharmacological extrapolation, not direct clinical evidence.

Why do people combine Mod GRF 1-29 with ipamorelin?

GHRH analogs (like Mod GRF 1-29) and GHRPs (like ipamorelin) stimulate GH release through different receptor pathways: GHRHR and GHS-R1a respectively. Co-administration of GHRH and GHRPs produces synergistic GH release 2-3 times greater than either alone. Ipamorelin is preferred because it selectively releases GH without raising cortisol or prolactin. No study has tested this specific combination in humans.

Is Mod GRF 1-29 legal?

Mod GRF 1-29 is not FDA-approved for any indication. It is classified as a research chemical, not a licensed pharmaceutical. WADA bans it under category S2 (peptide hormones). Products sold online are unregulated and may vary in purity, concentration, and sterility. The only FDA-approved GHRH analog is tesamorelin (Egrifta), which uses a different chemical modification.